249 related articles for article (PubMed ID: 15576036)
1. Structural basis for the activity of drugs that inhibit phosphodiesterases.
Card GL; England BP; Suzuki Y; Fong D; Powell B; Lee B; Luu C; Tabrizizad M; Gillette S; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY
Structure; 2004 Dec; 12(12):2233-47. PubMed ID: 15576036
[TBL] [Abstract][Full Text] [Related]
2. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
Card GL; Blasdel L; England BP; Zhang C; Suzuki Y; Gillette S; Fong D; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY
Nat Biotechnol; 2005 Feb; 23(2):201-7. PubMed ID: 15685167
[TBL] [Abstract][Full Text] [Related]
3. A substrate selectivity and inhibitor design lesson from the PDE10-cAMP crystal structure: a computational study.
Lau JK; Li XB; Cheng YK
J Phys Chem B; 2010 Apr; 114(15):5154-60. PubMed ID: 20349929
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.
Scapin G; Patel SB; Chung C; Varnerin JP; Edmondson SD; Mastracchio A; Parmee ER; Singh SB; Becker JW; Van der Ploeg LH; Tota MR
Biochemistry; 2004 May; 43(20):6091-100. PubMed ID: 15147193
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
6. A Unique Sub-Pocket for Improvement of Selectivity of Phosphodiesterase Inhibitors in CNS.
Wang Y; Ke H
Adv Neurobiol; 2017; 17():463-471. PubMed ID: 28956343
[TBL] [Abstract][Full Text] [Related]
7. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
Zoraghi R; Francis SH; Corbin JD
Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.
Weeks JL; Blount MA; Beasley A; Zoraghi R; Thomas MK; Sekhar KR; Corbin JD; Francis SH
Methods Mol Biol; 2005; 307():239-62. PubMed ID: 15988068
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of cyclic nucleotide hydrolysis in the phosphodiesterase catalytic site.
Salter EA; Wierzbicki A
J Phys Chem B; 2007 May; 111(17):4547-52. PubMed ID: 17425352
[TBL] [Abstract][Full Text] [Related]
10. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.
Gupta R; Kumar G; Kumar RS
Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):101-18. PubMed ID: 15834463
[TBL] [Abstract][Full Text] [Related]
11. Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity.
Matthiesen K; Nielsen J
Biochem J; 2009 Oct; 423(3):401-9. PubMed ID: 19689430
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
13. Homology modeling, docking studies and molecular dynamic simulations using graphical processing unit architecture to probe the type-11 phosphodiesterase catalytic site: a computational approach for the rational design of selective inhibitors.
Cichero E; D'Ursi P; Moscatelli M; Bruno O; Orro A; Rotolo C; Milanesi L; Fossa P
Chem Biol Drug Des; 2013 Dec; 82(6):718-31. PubMed ID: 23865680
[TBL] [Abstract][Full Text] [Related]
14. X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity.
Zhu J; Yang Q; Dai D; Huang Q
J Am Chem Soc; 2013 Aug; 135(32):11708-11. PubMed ID: 23899287
[TBL] [Abstract][Full Text] [Related]
15. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
16. Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond.
Weeks JL; Corbin JD; Francis SH
J Pharmacol Exp Ther; 2009 Oct; 331(1):133-41. PubMed ID: 19641165
[TBL] [Abstract][Full Text] [Related]
17. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Discovery of PDEs Inhibitors.
Li L; Chen W; Chen T; Ren J; Xu Y
Curr Top Med Chem; 2016; 16(9):917-33. PubMed ID: 26303429
[TBL] [Abstract][Full Text] [Related]
19. Structural and functional comparisons of nucleotide pyrophosphatase/phosphodiesterase and alkaline phosphatase: implications for mechanism and evolution.
Zalatan JG; Fenn TD; Brunger AT; Herschlag D
Biochemistry; 2006 Aug; 45(32):9788-803. PubMed ID: 16893180
[TBL] [Abstract][Full Text] [Related]
20. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).
Hu E; Kunz RK; Rumfelt S; Andrews KL; Li C; Hitchcock SA; Lindstrom M; Treanor J
Bioorg Med Chem Lett; 2012 Nov; 22(22):6938-42. PubMed ID: 23044369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
